New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
October 14, 2014
12:41 EDTGILDGilead retreats following Johnson & Johnson comments on HCV drug
Shares of Gilead (GILD), which has developed a hepatitis C treatment, are retreating after Johnson & Johnson (JNJ) said it would seek to make its own hepatitis C treatment accessible and competitive. Some investors believe that Johnson & Johnson's comments suggest that it will cut the price of its hepatitis C drug. WHAT'S NEW: Johnson & Johnson said on its earnings conference call today that it was "committed" to its treatment for hepatitis C virus, or HCV. The company added that it intends to remain competitive in the space and would look to make its HCV treatment, Olysio, accessible. In a separate development today, The Wall Street Journal reported that Abbvie (ABBV), which also has an HCV treatment, may have to consider pricing its HCV drug more aggressively after Gilead received FDA approval for Harvoni, the first combination pill approved to treat chronic HCV genotype 1 infection. One analyst quoted by The Journal, Roger Longman, said that AbbVie should consider pricing its drug at $76,000 for a 12 week regimen, representing a 20% discount to Harvoni, which will be priced at $94,500 for a full 12 week regimen. ANALYST REACTION: In a note to investors earlier today, RBC Capital analyst Michael Yee wrote that the weakness in Gilead's stock today has created a buying opportunity. Johnson & Johnson probably can't reduce the price of its Olysio drug much, since it is often used in combination with Gilead's Sovaldi, which costs $84,000 for 12 weeks, RBC Capital analyst Michael Yee wrote in a note to investors today. The price of AbbVie's treatment is unlikely to be much below Sovaldi's price, the analyst stated. WHAT'S NOTABLE: Gilead, along with a number of other drug companies, may also be under pressure because Ireland is reportedly closing its "Irish Double" tax loophole. Gilead is one of the companies that currently benefits from the "Irish Double," but Yee says that closing the loophole should only have a "minimal" impact on Gilead. PRICE ACTION: In early afternoon trading, Gilead fell 3.3% to $98.10, AbbVie gained 1.7% to $54.53 and Johnson & Johnson lost 0.6% to $98.52.
12:31 EDTINTCIntel October 32.5 straddle priced for 6% move into Q3
Subscribe for More Information
11:52 EDTGILDStocks with call strike movement; APC GILD
Subscribe for More Information
11:39 EDTINTCIntel technical comments ahead of earnings
The shares have outperformed the broader averages over the last three months. Removing today's bounce, the stock has been flat against the down performance of the averages. The trading pattern for the stock when viewed with a three-month window has been up sharply, sideways, and down sharply. That doesn't leave a great deal of room for trend interpretation other than traders being cautious into results. When we pull back to a 1-year view, the technical picture is strikingly different. Almost all of the gains in shares this year, up over 34% excluding today, has come since the early summer. That sharp rise then developed into a bearish rounding formation viewed on a closing basis. On an OHLC chart, the formation instead is an Island Top. That is, a bullish gap, the sideways move previously described, and a bearish gap from yesterday. That leaves the price action of the last several months isolated, an island, within the context of the longer term uptrend. Island Tops are usually considered extremely bearish on a technical basis, suggesting the up move has exhausted itself in a blow-off. If the news on earnings and outlook supports this bearish price interpretation, there could be significant downside risk. Levels to watch on the downside would be at $31.80, the bottom of the bullish gap from July, $30,03, and $28.10, the bottom of the bullish gap from June. A break below $28 might leave the shares back in the $24 to $26 range characteristic of the price action at the start of the year. If the news is positive, the first major resistance is at the 52-week high at $35.56 and then at $37.15.
11:10 EDTGILDGilead weakness today overdone, says Deutsche Bank
Subscribe for More Information
10:51 EDTGILDGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:41 EDTGILDGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:11 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
10:10 EDTINTCChip makers rise following Skyworks positive preannouncement
Shares of a number of semiconductor makers are climbing after one of the companies in the sector, Skyworks (SWKS), preannounced stronger than expected results. WHAT'S NEW: Skyworks, which develops chips for cell phones, raised its fourth quarter earnings per share outlook to $1.08 from $1.00. Analysts' consensus estimate was $1.01. The chip maker increased its Q4 revenue guidance to $718M from $680M. Analysts' consensus estimate was $679.5M. "Skyworks’ upwardly revised outlook demonstrates the broad-based strength of our business and our ability to capitalize on positive underlying market trends to connect everyone and everything, all the time,” said Skyworks CEO David Aldrich. "These multi-year technology trends are setting the stage for us to outperform the broader semiconductor industry in the December quarter and for the foreseeable future," the CEO added. WHAT'S NOTABLE: Skyworks' positive report comes less than a week after another semiconductor maker, Microchip (MCHP), preannounced lower than expected revenue and said it thought the sector had entered a correction. Semiconductor stocks have sold off sharply since Microchip's preannouncement and pessimistic comments. PRICE ACTION: In early trading, Skyworks surged 6.4% to $48.24, Intel (INTC) rose 1.5% to $31.94, NXP Semiconductors (NXPI) rose 1.2% to $54.55, STMicroelectronics (STM) advanced 2% to $6.82, and Avago Technologies (AVG) gained fractionally to $69.30.
10:05 EDTGILDAbbVie could cause Hep C price tipping point with aggressive pricing, WSJ says
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
09:37 EDTGOOGDomino's Pizza sees potential for additional 3.8K stores in top 15 markets
Says has 'robust' international business. Says its store count growing faster internationally than Pizza Hut or Papa Johns (PZZA). Pizza Hut is owned by Yum! Brands (YUM). Says now offering voice ordering for Apple's (AAPL) iPhone and Google's (GOOG) Android operating systems. Says in terms of the franchise's long-range outlook, sees global net units to increase 4%-6%, sees domestic SSS to increase 2%-4%, sees international SSS to increase 3%-6% and sees global retail sales to increase 6%-10%. Comments taken from the company's Q3 earnings conference call slide presentation.
09:14 EDTGILDJ&J sees FY14 pre-tax operating margin significantly improved vs. FY13
Subscribe for More Information
08:59 EDTGOOGGoogle October volatility elevated into Q3 and outlook
Subscribe for More Information
07:31 EDTGOOGGoogle says YouTube Preferred ads essentially sold out, WSJ reports
Subscribe for More Information
07:24 EDTINTCIntel gains government ally in China with new deals, Reuters says
Subscribe for More Information
06:36 EDTGOOG'Double Irish' tax arrangement poised to halt, itnews says
Ireland is positioned to enact legal revisions soon that will slowly cease its "Double Irish" tax agreement, which has allowed companies like Google (GOOG) and Apple (AAPL) to not spend billions of dollars worth of taxes, according to itnews, citing, two sources familiar with the situation. Reference Link
06:29 EDTINTCTSMC and rivals racing to pack computer power in each chip, WSJ says
Subscribe for More Information
06:19 EDTGOOGGoogle expands Express delivery service, to charge membership fee
Subscribe for More Information
06:02 EDTGOOGGoogle may be leading $500M funding round for Magic Leap, Re/code reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use